Idea Transcript
DAFTAR PUSTAKA 1. American Thoracic Society. Management of malignant pleural effusions. Am J Respir Crit Care Med 2000;162:1987-2001. 2. Antony VB, Loddenkemper R, Astoul P, Boutin C, Goldstraw P, Hott J, Rodriguez-Panadero F, Sahn SA. Management of malignant pleural effusions. Eur Respir J 2001;18:402-419. 3. Marel M, Stastny B, Melinova L, Svandova E, Light RW. Diagnosis of pleural effusions: experience with clinical studies, 1986 to 1990. Chest 1995;107:1598-1603. 4. Lee JH, Chang JH. Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, neuron-specific enolase, and cytokeratin 19 fragments in patients with effusions from primary lung cancer. Chest 2005;128:2298-2303. 5. Pasaoglu G, Zamani A, Can G, Imecik O. Diagnostic value of CEA, CA 19-9, CA 125 and CA 15-3 levels in malignant pleural fluids. Eur J Gen Med 2007;4(4):165-171. 6. Heffner JE, Klein JS. Recent advances in the diagnosis and management of malignant pleural effusions. Mayo Clin Proc. 2008;83(2):235-250. 7. Sahn SA. Malignant pleural effusions. In: Fishman AP, Elias JA, Fishman JA, Grippi MA, Senior RM, Pack AI, editors. Fishman’s pulmonary diseases and disorders. 4th ed. New York: McGraw-Hill Companies Inc; 2008:1505-1515. 8. Haas AR, Sterman DH, Musani AI. Malignant pleural effusions: management options with consideration of coding, billing, and a decision approach. Chest 2007;132:1036-1041. 9. Irawan A, Maranatha D. Peran CEA cairan pleura dalam diagnosis efusi pleura ganas kanker paru. J Respir Indo 2002;22:11-15. 10. Perhimpunan Dokter Paru Indonesia – Perhimpunan Onkologi Indonesia. Dalam: Jusuf A, Harryanto A, Syahruddin E, Endardjo S, Mudjiantoro S, Sutandio N, eds. Kanker paru jenis karsinoma bukan sel kecil. Pedoman nasional untuk diagnosis dan penatalaksanaan di Indonesia 2005. Jakarta: Indah Offset Citra Grafika; 2005:19-21. 11. Riantawan P, Sangsayan P, Bangpattanasiri K, Rojanaraweewong P. Limited additive value of pleural fluid carcinoembryonic antigen level in malignant pleural effusion. Respiration 2000;67:24-29. 53
Universitas Sumatera Utara
12. Salyer WR, Eggleston JC, Erozan YS. Efficacy of pleural needle biopsy and pleural fluid cytopathology in the diagnosis of malignant neoplasm involving the pleura. Chest 1975;67:536-539. 13. Antunes G., Neville E., Duffy J., Ali N., Pleural Diseases Group, Standards of Care Committee, British Thoracic Society. BTS guidelines for the Management of malignant pleural effusions. Thorax 2003;58.Suppl 2:ii29–38. 14. McKenna JM, Chandrasekhar AJ, Henkin RE. Diagnostic value of carcinoembryonic antigen in exudative pleural effusions. Chest 1980;78:587-590. 15. Porcel JM, Vives M, Esquerda A, Salud A, Perez B, Rodriguez PanaderoF. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. Chest 2004; 126:1757-1763. 16. Romero S, Fernandez C, Arriero JM, et al. CEA, CA 15-3 and CYFRA 21-1 in serum and pleural fluid of patients with pleural effusions. Eur Respir J 1996;9:17-23. 17. Shi H, Liang Q, Jiang J, Qin X, Yang H. Diagnostic value of carcinoembryonic antigen in malignant pleural effusion: a meta-analysis. Respirology 2008;13:518-527. 18. Garcia-Pachon E, Padilla-Navas I, Dosda D, Miralles-Llopis A. Elevated level of carcinoembryonic antigen in nonmalignant pleural effusions. Chest 1997;111:643-647. 19. Light RW. Pleural effusions related to metastatic malignancies. In: Pleural disease. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2007;10:133-161. 20. Pakki TR. Efusi pleura ganas. In: Kosasih A, Susanto AD, Pakki TR, eds. Diagnosis dan tatalaksana kegawatdaruratan paru dalam praktek seharihari. Jakarta: Sagung Seto; 2008:55-67. 21. Sahn SA. Pleural diseases related to metastatic malignancies. Eur Respir J 1997;10:1907-1913. 22. Syahruddin E, Hudoyo A, Arief N. Efusi pleura ganas pada kanker paru. J Respir Indo 2009;29(4):196-201. 23. Heffner JE. Diagnosis and management of malignant pleural effusions. Respirology 2008;13:5-20. 54
Universitas Sumatera Utara
24. Alsagaff H, Mukty HA, eds. Penyakit pleura. In: Dasar-dasar ilmu penyakit paru. Airlangga University Press; 2005:3:144. 25. Sinaga J. Efusi pleura eksudatif di poliklinik BP-4 pusat Medan/FKUSU/UPF Paru RS Dr.Pirngadi Medan [tesis]. Medan: Program Pendidikan Dokter Spesialis I.Penyakit Paru FKUSU, 1988. 26. Ang P, Tan EH, Leong SS, Koh L, Eng P, Agastan P, et al. Primary intrathoracic malignant effusion. Chest 2002;120:50-54. 27. Porta R, Crowley J, Goldstraw P. The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg 2009;15:4-9. 28. Light RW. Anatomy of the pleura. In: Pleural disease. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2007:1:1-6. 29. Broaddus VC, Light RW. Disorders of the pleura. In: Mason RJ, Murray JF, Broaddus VC, Nadel JA. Textbook of respiratory medicine. 3rd ed. Philadelphia: WB Saunders Company; 2000: 68:1913-1951. 30. Light RW. Clinical manifestations and useful tests. In: Pleural disease. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2007: 7:75-77. 31. Light RW. Diagnostic principles in pleural disease. Eur Respir J 1997;10:47-81. 32. Figueiras-Junior RD. Oncology: Tumor markers. Available from: http://www.medstudents.com.br/onco/onco1.html Updated November 2009. 33. Sharma S. Tumor markers in clinical practice: General principles and guidelines. Indian J Med Paediatr Oncol 2009;30:1-8. 34. Hansen M, Pedersen AG. Tumor markers in patients with lung cancer. Chest 1986;89:219S-224S. 35. Vladutiu AO, Brason FW, Adler RH. Differential diagnosis of pleural effusions – Clinical usefulness of cell marker quantitation. Chest 1981;79:297-301. 36. Baratawidjaja KG, Rengganis I. Imunologi tumor. In: Imunologi dasar. 8th ed. Jakarta: Balai Penerbit FKUI; 2009:16:451-457. 37. Wikimedia foundation. Carcinoembryonic antigen. Available from: Updated http://en.wikipedia.org/wiki/Carcinoembryonic_antigen. December 2009.
55
Universitas Sumatera Utara
38. Moses S. Carcinoembryonic antigenaka: CEA. Available from: Updated http://www.fpnotebook.com/GI/Lab/CrcnmbryncAntgn.html October 2008. 39. Allina Health System. Carcinoembryonic antigen measurement, pleural fluid. Available from: http://www.medformation.org/CCS/doc/Consumer_Lab/49/150223.htm Updated 5 April 2009. 40. Bunn PA. Tumor markers. In: Cecil textbook of medicine. 19th ed. Philadelphia: WB Saunders Company; 1992:1034-1037. 41. Wick MR. Pathology: cytology. In: Light RW, Lee YG, eds. Textbook of pleural diseases. 2nd ed. London: Hodder & Stoughton Ltd; 2008:23:301304. 42. Paganuzzi M, Onetto M, Marroni P, Filiberti R, Tassara E, Parodi S, Felletti R. Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma. Chest 2001; 119:1138-1142. 43. Sthaneswar P, Yap SF, Jayaram G. The diagnostic usefulness of tumour markers CEA and CA-125 in pleural effusion. Malaysian J Pathol 2002;24(1):53-58. 44. Light RW. Thoracentesis (diagnostic and therapeutic) and pleural biopsy. In: Pleural disease. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2007:28:376-392. 45. Abbott AxSYM system. Tumor markers CEA. Japan: Abbott Laboratories 2004. 46. Bales CE. Laboratory techniques. In: Koss LG, Melamed MR, eds. Koss’ diagnostic cytology and its histopathologic bases. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2006:44:1570-1634. 47. Sugito, Soeroso LS, Parhusip RS, Amir Z, Rusyda. Efusi pleura masif. Edisi Khusus No.80. Cermin Dunia Kedokteran; 1992:95-97.
56
Universitas Sumatera Utara